Translate Bio
https://translate.bio/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Translate Bio
The Dealmaking Landscape According To Sanofi
Monika Vnuk, head of Sanofi’s business development, says the best candidates are still commanding very high prices and outside inflammation and immunology, the French drugmaker is on the look-out for clinical rather than very early-stage assets.
Stock Watch: Sanofi’s Vaccine Gap-Filling Aspirations
Phase II studies of vaccines involve more variables than for drugs and these can be compounded by seasonality. This can make the time until vaccine approval longer than would be expected for drugs.
The Dealmaking Landscape According to Sanofi
Monika Vnuk, head of Sanofi’s business development, tells Scrip that the best candidates are still commanding very high prices and outside inflammation and immunology, the French drugmaker is on the look-out for clinical rather than very early-stage assets.
Sanofi Goes All In For Type 1 Diabetes With Provention Buy
Sanofi is taking full control of the recently approved type 1 diabetes prevention therapy Tzield by splashing out $2.9bn to acquire partner Provention.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
-
Drug Discovery Tools
- ADMET
- Other Names / Subsidiaries
-
- RaNA Therapeutics Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice